Issue Date: July 21, 2008
ViroPharma To Buy Lev For $443 Million
ViroPharma, in Exton, Pa., has reached an agreement to acquire Lev Pharmaceuticals, a New York City-based biopharmaceutical firm focused on developing treatments for inflammatory diseases, for an up-front payment of $442.9 million. Lev's Cinryze, a C1 inhibitor therapy for patients with hereditary angiodema, is currently under FDA review. Lev shareholders are also eligible for up to $175 million in regulatory and commercial milestone payments.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society